← Back to Search

Other

VLS-1488 for Advanced Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Volastra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For Dose Escalation: No available therapeutic options to provide clinically meaningful benefits in specific tumor types
ECOG Performance Status ≤ 1
Must not have
Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug
Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of CYP3A, and clinical inhibitors of MDR1 (P-gp) and BCRP
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests VLS-1488, a new drug for advanced cancers, to find the safest and most effective dose. It targets patients needing new treatment options and checks how the drug interacts with other medications and food.

Who is the study for?
This trial is for adults with advanced cancers who've already tried standard treatments. They should be able to perform daily activities with minimal assistance (ECOG ≤ 1), have measurable disease, and take pills without changing them. Not eligible if they have certain genetic mutations, brain metastases, previous KIF18A inhibitor treatment, or recent serious heart issues.
What is being tested?
The study tests VLS-1488's safety and early effectiveness in patients with various advanced cancers. It includes two parts: dose escalation to find the right amount of drug and dose expansion to see how well it works at that dose.
What are the potential side effects?
As this is a first-in-human study for VLS-1488, specific side effects are not yet known but may include typical reactions related to cancer drugs such as nausea, fatigue, allergic reactions or more serious complications depending on individual patient responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have no other treatment options that would significantly help my cancer.
Select...
I am fully active or can carry out light work.
Select...
I can swallow pills without needing to crush or dissolve them.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I haven't had fluid drained from my abdomen or chest in the last 28 days.
Select...
I can avoid medications that strongly affect certain liver enzymes and drug transporters.
Select...
My cancer has specific genetic mutations or is known to mutate quickly.
Select...
My cancer has spread to my brain or spinal cord.
Select...
I have been treated with a KIF18A inhibitor before.
Select...
I haven't had recent severe heart issues or a heart function below normal.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Dose Expansion: Exploration CohortsExperimental Treatment1 Intervention
Subjects with a selected single tumor type will be randomized 1:1 into Exploration Cohorts at two or more dose levels of interest. A subset of subjects will have additional assessments to examine the potential for VLS-1488 to interact with other drugs and the effect of food on VLS-1488 absorption.
Group II: Dose Expansion: Development CohortsExperimental Treatment1 Intervention
Subjects with other tumor types will be enrolled at a single dose level of interest. These Development Cohorts will be utilized to examine the preliminary efficacy of VLS-1488 in various tumor types.
Group III: Dose Escalation: Dose Escalation CohortsExperimental Treatment1 Intervention
Subjects will be enrolled at various doses and/or schedules of VLS-1488. These Dose Escalation Cohorts will be utilized to identify the MTD and to select dose levels for Dose Expansion.
Group IV: Dose Escalation: Backfill CohortsExperimental Treatment1 Intervention
Additional subjects may be enrolled at any dose level that does not meet de-escalation or elimination rules per the BOIN design. These Backfill Cohorts will be utilized to build additional data to support selection of doses and/or tumor types for further study in Dose Expansion.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for esophageal cancer include chemotherapy, radiation therapy, and immunotherapy. Chemotherapy targets rapidly dividing cancer cells to disrupt their growth and replication. Radiation therapy uses high-energy rays to damage the DNA of cancer cells, leading to their death. Immunotherapy, such as pembrolizumab and nivolumab, enhances the immune system's ability to detect and destroy cancer cells by inhibiting checkpoints like PD-1/PD-L1. These mechanisms are important for esophageal cancer patients as they help tailor treatment plans to effectively target the cancer while considering the patient's overall health and specific cancer characteristics.
Minimally Invasive Versus Open Esophageal Resection: Three-year Follow-up of the Previously Reported Randomized Controlled Trial: the TIME Trial.

Find a Location

Who is running the clinical trial?

Volastra Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
186 Total Patients Enrolled
~62 spots leftby Dec 2025